Next Article in Journal
HIV-1 Diversity in the Envelope Glycoproteins: Implications for Viral Entry Inhibition
Next Article in Special Issue
Th17 Lymphocytes in Respiratory Syncytial Virus Infection
Previous Article in Journal
Identifying the Viral Genes Encoding Envelope Glycoproteins for Differentiation of Cyprinid herpesvirus 3 Isolates
Previous Article in Special Issue
Apoptosis in Pneumovirus Infection
Viruses 2013, 5(2), 577-594; doi:10.3390/v5020577
Review

Respiratory Syncytial Virus: Current Progress in Vaccine Development

1
,
1
,
1
,
1
 and
1,2,*
1 Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA 2 Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, 858 Madison Avenue, Memphis, TN 38163, USA
* Author to whom correspondence should be addressed.
Received: 16 January 2013 / Revised: 1 February 2013 / Accepted: 4 February 2013 / Published: 5 February 2013
(This article belongs to the Special Issue Pneumoviruses and Metapneumoviruses)
View Full-Text   |   Download PDF [246 KB, 12 May 2015; original version 12 May 2015]

Abstract

Respiratory syncytial virus (RSV) is the etiological agent for a serious lower respiratory tract disease responsible for close to 200,000 annual deaths worldwide. The first infection is generally most severe, while re-infections usually associate with a milder disease. This observation and the finding that re-infection risks are inversely associated with neutralizing antibody titers suggest that immune responses generated toward a first RSV exposure can significantly reduce morbidity and mortality throughout life. For more than half a century, researchers have endeavored to design a vaccine for RSV that can mimic or improve upon natural protective immunity without adverse events. The virus is herein described together with the hurdles that must be overcome to develop a vaccine and some current vaccine development approaches.
Keywords: respiratory syncytial virus; candidate vaccines; protective immunity respiratory syncytial virus; candidate vaccines; protective immunity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Rudraraju, R.; Jones, B.G.; Sealy, R.; Surman, S.L.; Hurwitz, J.L. Respiratory Syncytial Virus: Current Progress in Vaccine Development. Viruses 2013, 5, 577-594.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert